OTC Cough, Cold & Allergy Medicine Market Overview, Trends and Growth Opportunities Forecasted till 2022

Dublin 2, Ireland, 2018-Feb-15 — /EPR Network/ — Majority of OTC cough, cold and allergy medicines manufacturers are actively focusing on raising the standards of functionality and effectiveness of their products. Growing consumer awareness and introduction of more effective anti-inflammatory drugs is facilitating the growth of the global OTC cough, cold and allergy medicines market. A recent report by Fact.MR provides in-depth analysis of the global OTC cough, cold and allergy medicines market for the forecast period 2017-2022, and offers pragmatic insights to lead market players towards devising & implementing informed strategies.

The scope of Fact.MR’s report is to analyze the global OTC cough, cold and allergy medicines market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. OTC cough, cold and allergy medicine manufacturers, suppliers and stakeholders in the global market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading magazines and journals pertaining to health and wellness.

Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=71

Following insights from Fact.MR’s global OTC cough, cold and allergy market will be important for market’s future growth

1.  The OTC cough, cold and allergy medicines market in Asia Pacific excluding Japan (APEJ) is anticipated to remain highly attractive throughout the assessment period. In 2017 and beyond, the region is projected to command for a noteworthy revenue share of the global market. This is primarily owing to dropping air quality and increase pollution that is resulting in higher occurrence of respiratory ailments.  In addition, rapid adoption of OTC medicines owing to their convenience of purchase and cost-efficiency is facilitating the growth of the market in the region.

2.  On the basis of drug type, antihistamine is anticipated to command for over one-third revenues share of the market by the end of 2017.  Antihistamines drugs help in restricting the histamine release from histamine-1 receptors, moreover these drugs can effectively treat watery eyes or runny nose, inflammation (redness), sneezing and swelling (edema).

3.   By OCT channel, pharmacies will continue to be the top OCT channel for sales of allergy, cold and cough drugs between 2017 and 2022. During the same time, the drug store segment is projected to retain its second spot.

4.   Based on dosage, the tablet segment is projected to command for a significant share of the market in terms of revenue and is likely to reach a valuation of nearly US$ 12,425 Mn over 2022.

Browse Full Report with TOC- https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-market

Asia-Pacific excluding Japan (APEJ) to Remain the Largest Market for OTC Cough, Cold and Allergy Medicines

Asia-Pacific excluding Japan (APEJ) is projected to remain the most lucrative market for OTC cough, cold and allergy medicines throughout the forecast period. In terms of revenue, APEJ is anticipated to account for an impressive share of the global market in 2017 and beyond. The region’s proximity to air pollution has led to the rise in prevalence of various respiratory disorders. Moreover, acceptance rate of OTC medicines is extremely high in the region owing to their low cost and convenience of purchase.

By drug type, antihistamine is projected to account for more than one-third share of the market in terms of revenue by 2017-end. Antihistamines drugs reduce the release of histamine from histamine-1 receptors and are commonly used for treating allergic reactions such as inflammation (redness), swelling (edema), watery eyes or runny nose and sneezing.

Pharmacies will remain the leading OTC channel for sales of cough, cold and allergy medicines during the assessment period.  Meanwhile, drug store OTC channel segment is expected to account for the second largest revenue share of the market by 2017-end.

By dosage, the tablet segment is estimated to account for more than 33% revenue share of the market and is expected to reach a valuation of around US$ 12,400 Mn towards the end of the forecast period.

Competition Tracking

Key companies profiled in Fact.MR’s report include Sanofi-Aventis, Johnson & Johnson Service, Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., AstraZaneca Plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Prestige Brands Holdings, Inc., Procter & Gamble Co., Bristol-Myers Squib Co., Merck & Co., and Allergen. Many of these market players are actively focusing on increasing their market presence and development of more efficient products.

Check Discount- https://www.factmr.com/connectus/sample?flag=D&rep_id=71

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized  Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/
Web: https://www.factmr.com/